List of works - Wim Wuyts

A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis.

scientific article published on 9 July 2018

Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation

scientific article published on 03 April 2020

An algorithm to tackle acute exacerbations in idiopathic pulmonary fibrosis

scientific article published in June 2008

Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.

scientific article

Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.

scientific article

BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis

scientific article published on 01 March 2019

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry

CYFRA 21.1 in bronchoalveolar lavage of idiopathic pulmonary fibrosis patients

scientific article published on 01 January 2015

Clinical behaviour of patients exposed to organic dust and diagnosed with idiopathic pulmonary fibrosis

scientific article published on 13 June 2018

Clinical use of biomarkers of survival in pulmonary fibrosis

scientific article published on 28 June 2010

Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis

scientific article published on 01 October 2016

Desquamative interstitial pneumonia: a systematic review of its features and outcomes

scientific article published on 23 June 2020

Determinants of survival in lung transplantation patients with idiopathic pulmonary fibrosis: a retrospective cohort study

scientific article published on 21 December 2018

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis

scientific article published on 01 November 2019

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

scientific article

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis

article published in 2019

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

scientific article published on 08 January 2020

Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial

scientific article published on 18 August 2020

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

scientific article published on 6 December 2016

European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity

scientific article published on 01 July 2016

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

scientific article

Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey

scientific article published on 21 October 2019

Gastro-oesophageal reflux and idiopathic pulmonary fibrosis: in search of evidence

scientific article published in September 2016

Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis: More than a Gut Feeling?

scientific article

Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis

article

Granulomatous lung disease in two workers making light bulbs

scientific article published on 26 July 2019

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management

scientific article published on 15 December 2018

Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease

scientific article published on 12 December 2019

Idiopathic pulmonary fibrosis: time for greater expectations?

scientific article published on 02 August 2018

Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in Fibrotic Hypersensitivity Pneumonitis: a retrospective cohort study

scientific article published on 16 January 2020

Insights into idiopathic pulmonary fibrosis in the real world

scientific article published on 01 July 2015

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

scientific article

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry

scientific article published on 24 October 2019

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis

scientific article published on 19 July 2018

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design

scientific article published on 29 September 2019

Multiplex protein profiling of bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis

scientific article published in January 2013

Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events

scientific article published on 13 December 2018

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis: Results of the INJOURNEY Trial

scientific article published on 10 September 2017

Outcome of lung transplantation in non-idiopathic pulmonary fibrosis interstitial lung disease

scientific article published on 06 August 2019

Pathology of idiopathic pulmonary fibrosis assessed by a combination of micro-computed tomography, histology, and immunohistochemistry

scientific article published on 10 September 2020

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment

scientific article published on 24 April 2019

Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a time.

scientific article published in June 2013

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

scientific article

Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis

scientific article published on 01 October 2018

Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes

scientific article published on 30 October 2019

Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.

scientific article

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

scientific article

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

scientific article published on 20 May 2018

Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials

scientific article published on 13 March 2019

Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design

scientific article published on 16 March 2018

Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study

scientific article published on 13 February 2020

Statins: cause of fibrosis or the opposite? Effect of cardiovascular drugs in idiopathic pulmonary fibrosis

scientific article published on 26 November 2020

Suggestions for improving clinical utility of future guidelines for diagnosis and management of IPF - results of a Delphi survey

scientific article published on 08 January 2021

The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis

scientific article published on 23 May 2019

Thin-Section CT Features of Idiopathic Pulmonary Fibrosis Correlated with Micro-CT and Histologic Analysis

scientific article published on 6 October 2016

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

scientific article published in February 2018

Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis

scientific article published on 5 December 2017

Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)

scientific article published on 01 September 2020

List of works by Wim Wuyts

A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis.

Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation

An algorithm to tackle acute exacerbations in idiopathic pulmonary fibrosis

Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.

Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.

BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry

CYFRA 21.1 in bronchoalveolar lavage of idiopathic pulmonary fibrosis patients

Clinical behaviour of patients exposed to organic dust and diagnosed with idiopathic pulmonary fibrosis

Clinical use of biomarkers of survival in pulmonary fibrosis

Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis

Desquamative interstitial pneumonia: a systematic review of its features and outcomes

Determinants of survival in lung transplantation patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey

Gastro-oesophageal reflux and idiopathic pulmonary fibrosis: in search of evidence

Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis: More than a Gut Feeling?

Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis

Granulomatous lung disease in two workers making light bulbs

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management

Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease

Idiopathic pulmonary fibrosis: time for greater expectations?

Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in Fibrotic Hypersensitivity Pneumonitis: a retrospective cohort study

Insights into idiopathic pulmonary fibrosis in the real world

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design

Multiplex protein profiling of bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis

Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis: Results of the INJOURNEY Trial

Outcome of lung transplantation in non-idiopathic pulmonary fibrosis interstitial lung disease

Pathology of idiopathic pulmonary fibrosis assessed by a combination of micro-computed tomography, histology, and immunohistochemistry

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment

Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a time.

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis

Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes

Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials

Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design

Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study

Statins: cause of fibrosis or the opposite? Effect of cardiovascular drugs in idiopathic pulmonary fibrosis

Suggestions for improving clinical utility of future guidelines for diagnosis and management of IPF - results of a Delphi survey

The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis

Thin-Section CT Features of Idiopathic Pulmonary Fibrosis Correlated with Micro-CT and Histologic Analysis

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis

Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)